Iran has produced a recombinant factor VIII drug, and hopes to mass-produce the medicine in the current Iranian calendar year, which started on March 20, 2016.
The drug, also dubbed AHF, is one of the proteins involved in blood coagulation. It is a protein which helps blood coagulation in consecutive reactions.
Lack of the factor causes Hemophilia A.
While there are over 100 recombinant drugs in the world, Factor VIII is one of the most complicated ones.
Iranian researchers made Coagulation factor 8 through a recombinant method. The researchers used biotechnology and genetic engineering and produced the efficient gene.
The product was processed in a reactor through biotechnology and biotechnology engineering.
The country would save at least $60m if it could mass-produce the drug.
In a hard-fought encounter, Iran’s national football team defeated Kyrgyzstan 3-2, maintaining their undefeated streak…
A major fire broke out in a chemical warehouse on Naser Khosrow Street in southern…
Syrian Foreign Minister Bassam al-Sabbagh, during a joint press conference with his Iranian counterpart in…
Russian President Vladimir Putin on Tuesday approved an updated nuclear doctrine, Reuters reported citing the…
Tehran has strongly condemned the new sanctions of the European Union and the United Kingdom…
Jomhouri-e Eslami, an Iranian newspaper known for its sharp critiques, has scolded Iran’s officials for…